1. Introduction {#sec1}
===============

Lung cancer is the most common cause of cancer-related deaths worldwide, with a five-year survival rate of less than 15% \[[@B1]\]. The high incidence of late-stage diagnosis and a lack of efficient therapeutic strategies remain key contributors to the dismal survival statistics. Thus, to improve lung cancer patient outcome, improvement in early detection and a better understanding of the underlying tumor biology that governs response to therapy are necessary. Response to systemic therapy has been shown to be strongly associated with a variety of clinical and molecular features. For example, the chemotherapeutics Avastin and Permetrexed have shown differential response or adverse effects in different histological subtypes of lung cancer \[[@B2], [@B3]\]. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have shown preferential efficacy in Asian females who typically harbor sequence mutations in *EGFR* as well as those individuals who harbored *EGFR* amplifications, *EGFR* mutations, and the absence of *KRAS*mutations \[[@B4]--[@B6]\]. Very recently, inhibitors to ALK rearrangement also showed significant response in patients who harbor this genetic alteration \[[@B7]\].

In addition to molecular features that can predict sensitivity, there are also examples of features that can predict resistance. In ovarian cancer, resistance to therapy was observed in those individuals who carried amplifications of genes such as P-glycoprotein as well as specific regions in the genome such as 19q12 and 20q11.22-q13.12 \[[@B8], [@B9]\]. With respect to lung cancer, while there are individuals who do respond to TKIs, a large proportion will develop resistance to these therapies by acquiring an additional *EGFR* mutation (T790M), amplification of the *c-MET* oncogene, or hypermethylation of the *PTEN* locus \[[@B10]--[@B12]\]. High levels of ERCC1 mRNA and protein, a key player in nucleotide excision repair, have been associated with resistance to platinum-based chemotherapy \[[@B13]\]. Similarly, low levels of RRM1/2 mRNA and protein were associated with favorable gemcitabine response in NSCLC patients \[[@B14]\].

Although alterations in protein-coding genes remain a main focus to elucidate sensitivity or resistance to chemotherapy, deregulation of microRNAs (miRNAs) has recently been shown to play a role in chemotherapy response \[[@B15]--[@B17]\]. miRNAs are small noncoding RNAs approximately 18--25 nucleotides in length that negatively regulate gene expression posttranscriptionally \[[@B18], [@B19]\]. miRNA biogenesis begins with a long, double-stranded RNA known as a pri-miRNA, typically hundreds to thousands of nucleotides in length, which is processed into sequentially shorter double-stranded RNA sequences by the endonucleases Drosha and Dicer that are of 70 and 22 nucleotides in size, respectively \[[@B20], [@B21]\]. Dissociation of the duplex and incorporation of the mature strand into the RNA-induced silencing complex (RISC) guides RISC to the target mRNA, where the miRNA exhibits its effect \[[@B22]\]. miRNAs bind target transcripts based on sequence similarity---typically in the 3′UTR of the transcript and sometimes in the 5′UTR and the coding region---resulting in inhibition of translation or transcript degradation \[[@B18], [@B19], [@B23]\].

The relevance of miRNA deregulation to cancer biology arises because increased expression of certain miRNAs can result in downregulation of tumor suppressor genes, while decreased expression of other miRNAs can lead to increased expression of oncogenes \[[@B20], [@B21]\]. Often located at chromosomal breakpoint regions, fragile sites, and minimal regions of loss of heterozygosity or amplification, miRNA loci are highly susceptible to genomic alterations and subsequently, deregulated expression \[[@B24]--[@B27]\]. Aberrant miRNA expression is a common feature of both dysplasia and cancer, and miRNA expression profiles have been associated with prognosis, disease progression, survival, and outcome prediction \[[@B28], [@B29]\]. Further, miRNA expression profiles have been found to be superior to global mRNA expression profiles for the accurate definition of cancer types \[[@B30], [@B31]\]. Lung cancer drug response has been associated with the deregulation of several miRNAs. For example, sensitivity of nonsmall cell lung cancer (NSCLC) to cisplatin treatment was linked to upregulation of *miR-181a*, while resistance was conferred by upregulation of *miR-630* \[[@B32]\]. Sensitivity to another chemotherapeutic agent, Gefitinib, was correlated with loss of *miR-128b* \[[@B33]\]. Several studies have shown that the overexpression of specific miRNAs, such as *miR-134* and *let-7a*, can increase drug sensitivity, demonstrating the therapeutic potential of miRNAs \[[@B34], [@B35]\].

In this study, we sought to determine the role of DNA copy number alterations at miRNA loci in chemotherapy response. As a proof of principle, making use of datasets generated by multiple institutions, encompassing we performed an integrative and comparative DNA dosage and expression alteration analysis of miRNA loci in highly sensitive and resistant lung cancer cell lines for 18 different chemotherapeutics. Using a rigorous, stepwise analysis strategy, we identified four miRNAs which were frequently gained and overexpressed in lung cancer cell lines resistant to one or two of five different chemotherapeutic agents. Subsequent gene expression and gene network analyses for each set of mRNA targets of a given miRNA revealed functions such as DNA replication and repair and cellular assembly and maintenance that were overrepresented in all four sets. These findings demonstrate the feasibility and the value of integrative analysis of multidimensional publicly accessible databases as a strategy for pharmacogenomics discovery.

2. Material and Methods {#sec2}
=======================

2.1. Drug Response Profiles of Cancer Cell Lines {#sec2.1}
------------------------------------------------

Drug response IC~50~ data for 18 different chemotherapeutics across 350 cancer cell lines (See Supplementary Material available online at doi: 10.1155/2011/474632 Supplemental Table  1) was generated as part of the Wellcome Trust Sanger Institute and Massachusetts General Hospital\'s (MGH) joint Genomics of Drug Sensitivity in Cancer Project. Data was downloaded from the following website: (<http://www.sanger.ac.uk/genetics/CGP/translation/compound_sens_data.shtml>). Briefly, IC~50~ is the required concentration of a particular drug to cause *in vitro* growth to be inhibited by 50%, and thus, a measure of drug effectiveness. A low IC~50~ indicates that a drug is very effective at inhibiting growth while a high IC~50~ indicates that a drug is less effective and thus requires a higher dosage to function. Of the 350 cancer cell lines, 73 cell lines were of lung origin.

2.2. Generation of DNA Copy Number Profiles for Cancer Cell Lines {#sec2.2}
-----------------------------------------------------------------

Affymetrix SNP 6.0 data for the cancer cell lines were obtained from the Wellcome Trust Sanger Institute CGP Data Archive (<http://www.sanger.ac.uk/genetics/CGP/Archive/>). Of the 73 lung cancer cell lines with drug response data, 67 of them also had matching SNP array hybridization data (Supplemental Table  2). SNP array data were normalized using default parameters in *Partek Genomics Suite* (*PGS*, Partek Inc, St. Louis, MI). Whole genome copy number profiles were visualized using *SIGMA^2^* software \[[@B36]\].

2.3. miRNA and mRNA Expression Data for Cancer Cell Lines {#sec2.3}
---------------------------------------------------------

The current annotation of autosomal miRNAs and their genomic coordinates were obtained from the *UCSC Genome Browser* (<http://www.genome.ucsc.edu/>) using the NCBI36/hg18 mapping \[[@B37]\]. miRNA and mRNA expression profiles for lung cancer cell lines were downloaded from the Broad Institute (<http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi>) under the "Sanger Cell Line Project." Affymetrix HG-U133A mRNA expression data were *RMA*-normalized using the "affy" package in *Bioconductor* in *R* \[[@B38]--[@B40]\]. Mapping of probes to genes was performed using the Affymetrix NetAffx annotation file (version NA31). Of the 73 lung cancer cell lines with drug response data, 64 had matching miRNA expression while 68 had matching mRNA expression data (Supplemental Table  2).

2.4. Determination of Predicted miRNA Targets {#sec2.4}
---------------------------------------------

*TargetSpy* (version 1.0) and *TargetScan* (version 5.1) miRNA target prediction software were used to identify mRNA targets for further analyses \[[@B41]--[@B44]\]. For *TargetSpy*, the "no seed requirement, high sensitivity" set of targets were used, while for *TargetScan*, the nonconserved miRNA-mRNA targets were used. For the miRNAs that were further assessed for target analysis, only miRNA-mRNA target pairs that were present in both databases were assessed for gene expression differences.

2.5. Statistical Analysis {#sec2.5}
-------------------------

For DNA alteration analysis, copy number profiles of the cancer cell lines were determined against a pooled reference comprised of 72 cytogenetically normal individuals in the HapMap collection. SNP 6.0 data for the HapMap individuals were obtained through Affymetrix. Subsequently, to determine copy number gains and losses, copy number profiles were subjected to segmentation analysis using the "Genomic Segmentation" algorithm in PGS with the following parameters: minimum genomic markers = 20, *P*-value threshold for adjacent regions having significantly different means = 1 × 10^−6^, and *P*-value threshold for deviation from normal (diploid) copy number = 1 × 10^−6^. In addition to meeting *P*-value thresholds, a region was deemed gained if the cell line had \>2.3 copies while a region was deemed lost if the cell line has \<1.7 copies. For each cell line, the copy number status for individual miRNA loci were determined by mapping the genomic coordinates of the miRNA loci to the identified regions of alteration.

To determine miRNA loci in differentially altered regions of copy number between highly resistant and sensitive cell lines, for each chemotherapeutic, cell lines were ranked based on their IC~50~ value. The frequency of copy number gain, loss, and retention were compared between the top 1/3 and bottom 1/3 of cancer cell lines using a 3 by 2 Fisher\'s exact test. A miRNA was deemed significant if the *P* value from the Fisher\'s exact test was ≤.05.

For miRNA and mRNA expression analysis, similar to the differential copy number analysis, cell lines were ranked based on IC~50~ for each drug. Subsequently, for each miRNA, the expression in the top and bottom tertiles of cell lines was compared using a nonparametric Mann Whitney *U* test. A miRNA was deemed significant if the *P* value from the Mann Whitney *U* test was ≤.05.

Upon identifying which lung cancer cell lines (LCCLs) contained matching DNA copy number and drug response profiles, for each chemotherapeutic, we compared the patterns of copy number alteration between the most sensitive and resistant LCCLs for 636 miRNA loci. Of the resulting differentially altered miRNA identified using the above statistical criteria, we filtered out those miRNAs which were both preferentially gained and lost in either highly resistant or highly sensitive LCCLs. We defined these variably altered miRNAs as those whose differential alteration frequency (DAF) of gain, frequency of gain in highly resistant minus the frequency of gain in highly sensitive, was within 10% of the DAF of loss, which is the frequency of loss in highly resistant minus the frequency of loss in highly sensitive. In parallel, upon identifying LCCLs with both miRNA expression and drug response profiles, we compared the miRNA expression profiles between the most sensitive and resistant LCCLs for 254 miRNAs using the above-mentioned statistical methods. Although 418 unique miRNAs are represented on the microarray platform, we restricted this analysis to the 254 miRNAs that were expressed in at least 4 LCCLs. Subsequently, for each drug, we identified the miRNAs which were both significantly different at the DNA copy number and expression levels that matched in the same direction that is, if a miRNA had higher copy number in the highly resistant LCCLs as compared to the highly sensitive LCCLs, then the expression would also have to be higher, and vice versa. Next, for each significant miRNA, bioinformatic analysis was performed to identify target mRNAs, and mRNA expression profiles for these genes were compared in a similar manner to that performed in the differential DNA copy number and miRNA expression analyses (using TargetSpy and TargetScan; see above). Restricting to those targets whose mRNA expression profiles negatively correlate with miRNA expression profiles, we performed gene network and function analysis using *Ingenuity Pathway Analysis* to identify significantly overrepresented functions that were common to all sets of differentially expressed miRNA targets. A flow chart illustrating this strategy is shown in [Figure 1](#fig1){ref-type="fig"}.

2.6. Gene Network and Pathway Analysis {#sec2.6}
--------------------------------------

For each miRNA, the set of differentially expressed target genes were analyzed using *Ingenuity Pathway Analysis* (Ingenuity Systems, Redwood City, CA) to determine statistically overrepresented networks and pathways. Briefly, a right tailed Fisher\'s exact test was employed to calculate a *P*-value for the probability that enrichment of functions within the gene list of interest and the entire list of genes in the human genome is due to chance alone. Only the *Molecular and Cellular Functions* within the *Biological Functions* analysis were assessed.

3. Results {#sec3}
==========

3.1. Copy Number Alterations of miRNA Loci Correlate with Drug Response in Lung Cancer Cell Lines {#sec3.1}
-------------------------------------------------------------------------------------------------

Sixty seven lung cancer cell lines with available IC~50~ data were used to analyze miRNA copy number alterations. For each drug, cell lines were sorted based on IC~50~ values and the frequencies of DNA copy number gain, loss, and retention were compared between the highest (most resistant, *n* = 22) and the lowest (most sensitive, *n* = 22) tertile of cell lines. Of the 636 miRNAs assessed, 307 miRNAs (48.3%) were significantly different between high and low IC~50~ for at least one drug, and 20 miRNAs (3.1%) were different for at least four drugs (*P* ≤ .05 Fisher\'s exact test, [Table 1](#tab1){ref-type="table"}, Supplemental Table  3). In addition, among the 307 miRNAs, 58.4% were either more frequently gained in high IC~50~ or more frequently lost in low IC~50~ while 23.6% were either more frequently lost in high IC~50~ or more frequently gained in Iow IC~50~ lung cancer cell lines. The remaining 41 miRNAs (17.9%), although significantly different, had less than a 10% DAF difference between resistant and sensitive lines and were, therefore, deemed variably altered (see methods) and subsequently removed. This brought the total number of miRNAs with significant differences in copy number to 266 ([Figure 2](#fig2){ref-type="fig"}). In terms of the drug with the most striking pattern of differential alteration between high and low IC~50~ cell lines, TAE684, a small molecule ALK fusion kinase inhibitor, had 66 miRNAs that were significantly different between the most resistant and most sensitive cell lines ([Figure 3](#fig3){ref-type="fig"}). Conversely, *miR-662* was the most frequently differentially-altered miRNA across all of the drugs, appearing significant in 6 of 18 drugs.

3.2. miRNA Expression Levels Correlate with Drug Response in Lung Cancer Cell Lines {#sec3.2}
-----------------------------------------------------------------------------------

miRNA expression was assessed in 64 lung cancer cell lines using a similar method to that applied for identifying copy number alteration differences, comparison of the highest and lowest tertile of cell lines (*n* = 21) based on IC~50~ values for each drug. miRNA expression profiles were available for 498 probes measuring 418 unique miRNAs. However, a number of miRNAs have little to no expression. To account for these cases, miRNAs with expression in less than four cell lines were removed, leaving 292 probes which corresponded to 254 unique miRNAs ([Figure 2](#fig2){ref-type="fig"}). One hundred thirty four miRNAs (represented by 146 probes) of the 254 (52.8%) miRNAs with available expression data were significant in at least one drug (*P* ≤ .05, Mann Whitney *U* test) (Supplemental Table  4), with 18 miRNAs significant in at least four drugs ([Table 2](#tab2){ref-type="table"}). Of the 134 differentially expressed miRNAs, 40% had higher expression in high IC~50~, while 60% had higher expression in low IC~50~ lung cancer cell lines. HKI-272 had the most miRNAs \[[@B30]\] that were significantly different at the expression level ([Figure 4](#fig4){ref-type="fig"}), and *miR-625* was the most frequently differentially expressed miRNA, appearing significant in 7 of 18 drugs.

3.3. Integrative Analysis of miRNA Gene Dosage and Expression Levels in Lung Cancer Cell Lines {#sec3.3}
----------------------------------------------------------------------------------------------

To determine if miRNA dosage modulates expression, we compared the 266 miRNAs differentially altered at the copy number level and the 134 miRNAs differentially expressed in at least one of the drugs analyzed. Considering only those miRNAs that were significant at both the copy number and miRNA expression level for the same drug, the intersection of these two lists yielded five miRNAs, *miR-10b*, *-191,*-*193b*, *-328*, and *-628* ([Figure 2](#fig2){ref-type="fig"}). Of these five, only expression of four miRNAs, *mir-10b, -193b, -328*, and *-628* matched the direction of their respective copy number alterations. For example, *miR-628* is more frequently gained in high IC~50~ lines compared to low IC~50~ lines treated with agent PF-2341066 and also shows higher expression in high IC~50~ lines compared to low IC~50~ lines ([Table 3](#tab3){ref-type="table"}), whereas *miR-191* is frequently gained in low IC~50~ lines when treated with TAE684, but shows higher expression in high IC~50~ lines.

3.4. Gene Expression Analysis of mRNA Targets of miR-10b, miR-193b, miR-328, and miR-628 {#sec3.4}
----------------------------------------------------------------------------------------

The target prediction software*TargetScan* and *TargetSpy* were used to identify putative mRNA targets of miRNAs found to be significantly different at the copy number and miRNA expression levels between high-IC~50~ and low-IC~50~ cell lines. For the four miRNAs (*miR-10b*, *miR-328*, *miR-193b*, and *miR-628*) identified by integrative analyses, only miRNA-mRNA targets present in both databases were used for further analysis.

*miR-10b* was identified as having a significant association with response to the proteosome inhibitor MG-132. In total, target prediction analysis found 636 genes that were deemed as putative targets of *miR-10b* (Supplemental Table  5). Comparison of the gene expression profiles between lung cancer cell lines with high and low IC~50~ for MG-132 revealed 48 of these target genes to be differentially expressed (*P* ≤ .05, Mann Whitney *U* test), with 32 of them showing the expected direction of differential expression (i.e., anticorrelated mRNA expression to miRNA expression) ([Table 4](#tab4){ref-type="table"}).

Interestingly, *miR-193b* alteration was significantly associated with response to two therapeutics: AZ628 and MK0457 (RAF and aurora kinase inhibitors, resp.). When a similar analysis to *hsa-miR-10b* was performed for *miR-193b*, 518 genes were identified as putative targets of *miR-193b*(Supplemental Table  5). For the analysis of gene expression between highly sensitive and resistant AZ628 cells, 28 of these targets were differentially expressed, with ten of these genes matching the expected direction of differential expression. For MK-0457, 67 of these target genes were differentially expressed with over half (37) matching the expected direction ([Table 4](#tab4){ref-type="table"}).

Alteration of *miR-328* was significantly associated with the response to Hsp90 inhibitor Geldanamycin in lung cancer cell lines. Of the 437 genes targeted by *miR-328*, 49 of these genes were significantly differentially expressed between highly resistant and sensitive cell lines, with 31 of the genes matching the expected direction (Supplemental Tables  5 and  4). Finally, for *miR-628*, whose alteration was significantly associated with the MET inhibitor PF-2341066 response, 392 targets genes were identified with 49 of them being differentially expressed and 22 of those in the appropriate direction (Supplemental Tables  5 and  4).

4. Discussion {#sec4}
=============

Chemotherapy response can be influenced by a number of clinicopathological and molecular factors. At the molecular level, while a large focus revolves around the role of activating and inactivating sequence mutations as well as copy number amplifications and deletions in protein coding genes, there has been an increasing emphasis on examining the role of miRNAs and response to chemotherapy. Recent studies have focused on differentially expressed miRNAs in conjunction to resistance and sensitivity to a variety of chemotherapeutics \[[@B32]--[@B35], [@B45], [@B46]\]. However, the influence of copy number alterations at miRNA loci (or gene dosage) in the context of drug response has not been thoroughly investigated. To this end, we have performed an integrative analysis of genome-wide miRNA copy number, miRNA expression, mRNA expression, and drug sensitivity data from 18 different chemotherapeutics on a panel of lung cancer cell lines to identify miRNAs that are significantly different at the copy number and expression levels between the most sensitive and resistant cell lines for a given drug.

Upon comparison of the 636 annotated miRNAs throughout the human genome, it was found that 266 of them revealed significant differences in copy number alteration pattern between sensitive and resistant cancer cell lines for at least one drug (Supplemental Table  3). Moreover, of the 266 miRNAs, there were more miRNAs with increased copy number for the highly resistant versus the highly sensitive lung cancer cell lines than vice versa. The miRNA that was found to have a differential pattern of copy number alteration between sensitive and resistant cancer cell lines for the most drugs was *miR-662*, and, conversely, the drug with most significantly different miRNAs was TAE684. *miR-662* is located on chromosomal region 16p13.3 and was found to be more frequently gained in cell lines highly resistant to AZ628, Erlotinib, Geldanamycin, Gö-6976, HKI-272 (Neratinib), and MK-0457. All of these drugs, except for Geldanamycin, which is an antibody that targets HSP90, are kinase inhibitors \[[@B47]\]. While not much is known of *miR-662*, it was recently shown that it is transiently upregulated in response to high doses of X-ray radiation in human fibroblasts \[[@B48]\]. It should also be noted that *miR-124-2*, *miR-1285-2,* and *miR-548h-2* were significantly altered for five drugs ([Table 1](#tab1){ref-type="table"}). Similar to *miR-662*, little is known of *miR-548h-2*. However, *miR-124* has been shown to play a tumor suppressive role in cervical cancer, hepatocellular carcinoma, and glioblastoma, while *miR-1285* inhibits p53 and p21 expression by targeting the 3′UTR of *p53*transcript \[[@B49]--[@B52]\].

To identify differentially expressed miRNAs in our dataset, we employed the same approach used to identify differential copy number alterations by assessing the expression of 254 miRNAs in 64 lung cancer cell lines. We identified 134 unique miRNAs significantly different at the expression level between resistant and sensitive lines in at least one drug. Of which, 40% overexpressed in highly resistant and 60% overexpressed in highly sensitive lung cancer cell lines. Of these 134 miRNAs, *miR-625,*about which little is known regarding function, was the most frequently differentially expressed. It was significantly differentially expressed in the analyses of agents Paclitaxel, HKI-272, Gö-6976, Erlotinib, Rapamycin, PHA665752, and MG-132. In terms of the drug comparisons with the highest number of differentially expressed miRNAs, the comparison between LCCLs highly sensitive and resistant to HKI-272, an irreversible tyrosine kinase inhibitor of HER2, revealed 30 differentially expressed miRNAs.

Previous studies of miRNA deregulation with respect to response of some of the drugs used in our analyses have identified a number of miRNAs whose expression correlates with drug sensitivity. For example, underexpression of *miR-34a* and overexpression of *miR-125b*, *2*-*21*, -*222*, and -*923* confer Paclitaxel resistance in prostate cancer \[[@B53]\] and breast cancer \[[@B54]\], respectively, while for hepatocellular carcinomas expression of *let-7c* \[[@B55]\], *miR-122* \[[@B56]\] and *miR-193b* \[[@B57]\] confer sensitivity to Sorafenib. Notably, Sorafenib is a multikinase inhibitor with highest potency for RAF; this is consistent with our findings that link *mir-193b* with resistance to the RAF inhibitor AZ628. In addition, underexpression of *miR-130a* and *-126* was correlated with resistance to Paclitaxel \[[@B58]\] and Imatinib \[[@B59]\], respectively. From our analyses, we observed *miR-130* and *-126* to be overexpressed in lung cancer cell lines sensitive to Paclitaxel and Imatinib.

Cancer genomes are characterized by widespread genetic aberrations including high-level amplifications, deletions, DNA methylation, mutations, and chromosomal rearrangements. Within the hundreds of alterations in a cancers genome, only a small subset of these alterations drive tumor initiation and progression and DNA alterations with corresponding expression alterations are more likely to contribute to tumorigenesis \[[@B60], [@B61]\]. To identify miRNAs likely implicated in drug resistance, we integrated the 266 miRNAs that were significantly different at the copy number level and the 134 miRNAs that were significantly different at the expression level and subsequently filtered for those miRNAs that were differentially expressed and altered in the same drug. Our analysis identified four miRNAs, *miR-10b*, -*193b*, -*328*, and -*628*, that met these criteria. While the overlap of significant miRNAs in the same drug is minimal, stringent selection criteria such as *P* ≤ .05 for both copy number and expression alterations, and limited miRNA expression data, likely contributed to the small number of overlapping miRNAs. Importantly, many of the miRNAs most frequently differentially altered at the copy number level (128 of 266, 48.1%) were not represented on the microarray platform. Moreover, when we factored in our expression criteria of expression in at least four cell lines, the number of miRNAs with expression profiles and significantly different copy number alterations was reduced to 66. The copy number profiles of these miRNAs suggest they may play an important role in drug resistance, dictating the importance and need to assess these uninvestigated miRNAs at the expression level.

The observation that *miR-10b* is differentially gained and overexpressed in resistant cell lines treated with MG-132 is consistent with previous findings (Figures [5(a)](#fig5){ref-type="fig"} and [5(b)](#fig5){ref-type="fig"}). *miR-10b* is an oncomir whose overexpression has been identified in a variety of cancers \[[@B62]--[@B67]\]. Specifically, overexpression of *miR-10b* has been demonstrated to promote the development of metastatic disease in breast cancer and correlate with clinical breast cancer progression, poor overall survival in gastric cancer, and higher grades of malignant glioma. It was also found to be an effective therapeutic target by using antagomirs to reduce expression of *HOXD10,* subsequently suppressing breast cancer metastasis \[[@B62], [@B64], [@B66], [@B68]\]. Bioinformatic and gene expression analysis of mRNA targets of *miR-10b* revealed 32 of 636 target genes that were underexpressed in highly resistant cell lines, which have high expression of *miR-10b*. Amongst the identified genes was *RAD1*([Figure 5(c)](#fig5){ref-type="fig"}). RAD1 is part of a complex of proteins known as the 9-1-1 complex, which functions as a heterotrimeric cell cycle checkpoint \[[@B69]\]. The complex, which functions in DNA repair, is recruited to the site of DNA damage or incomplete replication where it recruits DNA polymerases and DNA repair enzymes. RAD1 has been shown to be important in preventing tumor development in response to DNA damage in mice, whereas deletion of *RAD1* greatly increased the susceptibility for skin tumor development \[[@B70]\]. In addition, RAD1 is an important component of nucleotide excision repair (NER) which can have drastic effects on chemotherapy drug response. In drugs that instill double stranded DNA breaks, such as the platinum based treatment Cisplatin, upregulation of NER increases drug resistance while in certain non-DNA damage based chemotherapies, downregulation of NER has been shown to increase resistance \[[@B71], [@B72]\]. In NSCLC patients that have low expression of ERCC1, a gene also involved with NER, have decreased survival when compared to patients with high ERCC1 expression \[[@B73]\], and in both murine and human cells, low XPC expression, another gene involved in NER, correlated with resistance to the Doxorubicin derivative, Nemorubicin \[[@B72]\]. Intriguingly, one of the overrepresented functions identified by *Ingenuity Pathway Analysis* of the 32 differentially expressed target genes was *DNA Replication, Recombination, and Repair* ([Figure 6](#fig6){ref-type="fig"}).

Expression patterns of *miR-193b* in human cancers, unlike *miR-10b*, are largely variable. High expression of *miR-193b* is frequently observed in head and neck squamous cell carcinomas and is associated with a high risk of metastatic disease in uveal melanoma \[[@B74], [@B75]\]. Conversely, in other cancer types, overexpression of *miR-193b* has elicited increased tumor suppression as well as sensitivity to specific chemotherapeutics \[[@B57], [@B76], [@B77]\]. Moreover, conflicting results have also been observed within a given cancer type. In malignant cutaneous melanoma, overexpression of *miR-193b* predicts disease outcome and is associated with poor survival, while induced overexpression in cell lines repressed proliferation through the downregulation of Cyclin D1 \[[@B78], [@B79]\]. Subsequent gene expression analysis of target mRNAs of *miR-193b* revealed 10 genes that were underexpressed in cell lines highly resistant to AZ628and 37 genes that were underexpressed in cell lines highly resistant to MK-0457. One of the target genes that was also differentially expressed was *IKAROS family zinc finger 1* (*IKZF1*). This transcription regulating gene functions through associations with complexes that are both histone deacetylase (HDAC)-dependent and HDAC-independent \[[@B80]\]. Previous studies have shown that nonhigh-risk ALL9 patients with *IKZF1* deletions show a 12-fold higher rate of relapse compared to patients without *IKZF1* deletions and *IKZF1* deletion has also been implicated in tyrosine kinase inhibitor (TKI) resistance and disease progression in patients with chronic phase- (CP-) chronic myeloid leukemia (CML) \[[@B81], [@B82]\]. Overexpression of an Isoform of IKZF1 lacking a DNA binding domain, IK6, in acute lymphoblastic leukemia (ALL) patients with the Philadelphia chromosome has also been associated with TKI resistance \[[@B83]\]. Interestingly, MK-0457 is a small molecule inhibitor chemotherapy drug that targets aurora kinase. Underexpression of *IKZF1* as a result of *miR-193b* targeted degradation may increase resistance to MK-0457 in a similar mechanism to TKI resistance.

Similar to *miR-193b*, evidence supporting the role of *miR-328* in cancer is also unclear. In lung adenocarcinoma, *miR-328* has been shown to be overexpressed in tumor tissue relative to matched nonmalignant tissue regardless of *EGFR* or *KRAS* mutation status \[[@B28]\]. However, in other cancer types, *miR-328* underexpression, for example, enables drug resistance through the upregulation of *ABCG2* and correlates with cancer progression \[[@B84]--[@B86]\]. Our analyses revealed *miR-328* to be gained and overexpressed in lung cancer cell lines resistant to Geldanamycin, an antibody against HSP90. Target and gene expression analysis of *miR-328* identified 31 genes underexpressed in cell lines highly resistant to Geldanamycin, with one of the targets being the *Vitamin D receptor*(*VDR*). *VDR* and its downstream components, have been previously shown to have antiproliferative effects in a wide variety of cancer types. The anticancer effects of VDR signaling are mostly mediated through its active metabolite, 1,25-dihydroxyvitamin D (calcitriol), which has been shown to exhibit anti-inflammatory effects as well as the suppression of tumor angiogenesis, invasion, and metastasis \[[@B87], [@B88]\]. Expression of *VDR* has also been shown to be associated with increased survival in breast, colorectal cancer, and cholangiocarcinoma. It has been recently shown that nuclear VDR status may be a prognostic marker of improved survival in patients with NSCLC \[[@B88]\]. Another intriguing finding for *miR-328*-associated mRNAs is the implication of both H(+)-monocarboxylate cotransporter (MCT) proteins 1 and 4 (SLC16A1/MCT1 and SLC16A3/MCT4). MCT1 and 4 are involved in lactate uptake and pH balance. Inhibition of MCT1 in tumors can shift aerobic cancer cells from oxidative phosphorylation (lactate metabolism) to glycolysis (glucose), resulting in the death of hypoxic tumor cells due to glucose deprivation \[[@B89]\].

Relatively little has been reported with regard to the role of *miR-628*. A recent study revealed that *miR-628* was expressed in neuroblastomas with favorable prognosis, while those with unfavorable prognosis were devoid of expression, suggesting a tumor suppressive role in this type of cancer \[[@B90]\]. From our analyses, we identified *miR-628* to be gained and overexpressed in resistant lung cancer cell lines treated with agent PF-2341066, a MET and ALK kinase inhibitor which has recently shown tremendous efficacy in a subset of lung cancer patients \[[@B7]\]. While the direction of expression contradicts the findings in neuroblastoma, miRNA tissue specificity may play a role in differential expression patterns. Regardless, further analysis of *miR-628* is required to better elucidate its role in human cancers. Target and gene expression analysis of *miR-628* revealed 22 genes which were underexpressed in cell lines highly resistant to PF-2341066, with one of these differentially expressed being *caspase 3* (*CASP3*). *CASP3* is a gene involved in the caspase apoptosis cascade by activating caspases 6, 7, and 9 through cleavage \[[@B91]\]. Moreover, it is also used as a general indicator of cell death and apoptosis. Notably, PF-2341066, which functions as a TKI inhibitor, was found to induce the caspase cell death cascade *in vitro* through increased levels of CASP3 \[[@B92]\]. Thus, *CASP3* downregulation, as a result of *miR-628* targeting, may play a significant role in resistance to PF-2341066.

While all involved in response to different drugs, the targets of these miRNAs share certain biological functions. [Figure 6](#fig6){ref-type="fig"} illustrates the functions in which the targets of all four miRNAs participate at a statistically significant level. Broadly, if roles such as cellular maintenance and DNA repair were compromised, such cell populations could develop tolerance to the accumulation of mutations, some of which could dictate resistance. Participation in small molecule biochemistry has implications in the alteration of how these administered drugs are processed. Cellular organization and cell-to-cell signaling, if altered, could confer a more invasive phenotype, contributing to drug resistance.

5. Conclusions {#sec5}
==============

In conclusion, we have demonstrated our method of integrative analysis of multiple dimensions of data including genome-wide miRNA copy number, miRNA expression, mRNA expression, and drug sensitivity data, all available in the public domain, can be a powerful tool to identify miRNAs and genes involved in drug sensitivity. Through these initial analyses, we have identified miRNAs that may have a role in conferring chemoresistance to a number of drugs. Further *in vitro* and *in vivo* analyses of the miRNAs and their respective mRNA targets will be necessary to confirm the findings from this study. In addition, given that nearly half of the miRNAs that were differentially altered were not even represented on the miRNA platform analyzed, evaluation of these miRNAs may prove fruitful when new data becomes available. It should also be noted that miRNA target prediction approaches and algorithms are constantly evolving and increasing number of miRNA-mRNA interactions being experimentally validated, potentially revealing important target genes that are not currently implicated. Finally, since the MGH/Sanger collaboration aims to generate drug response profiles for a large number of chemotherapeutics in over 1000 cancer cell lines, as more data becomes available, our approach could identify candidate miRNAs that are associated with multiple drugs which have similar mechanisms of action. Moreover, our strategy could also be repeated in a more specific and clinically relevant manner, which could ultimately lead to the identification of prognostic biomarkers and therapeutic indicators for better disease management and patient outcome.
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![The search for drug response-related miRNAs began with data acquisition from several independent databases. Drug response data for lung cancer cell lines (LCCLs) was integrated independently with copy number and expression data, and unique filtering criteria were applied. The integration of all three dimensions applied further filtration criteria, and the remaining miRNAs underwent predicted target analysis. The resulting mRNA target expression was anticorrelated with miRNA expression, and cellular functions of the final mRNA target list were derived by *Ingenuity Pathway Analysis*.](JBB2011-474632.001){#fig1}

![Flowchart summarizing the process for the identification of the four miRNAs which correlated significantly with drug response.](JBB2011-474632.002){#fig2}

![Comparison of the frequency of alteration of 636 miRNA loci between highly sensitive and highly resistant lung cancer cell lines (LCCLs) to agent TAE684. Highly sensitive LCCLs were represented by the lowest tertile of IC~50~ while the highly resistant were represented by the highest tertile of IC~50~. miRNA genomic position information was obtained from the UCSC Genome Browser database \[[@B37]\], and miRNAs on chromosomes X and Y were excluded. Copy number alterations frequencies were plotted using *SIGMA^2^* software \[[@B36]\]. Vertical lines denote the frequency of alteration, where 1 or −1 signifies the alteration that occurs in 100% of samples. Horizontal bars depict miRNAs, with the frequency of copy gains and losses of each miRNA displayed to the right and left of 0, respectively. miRNAs disrupted in resistant lines are displayed in red, those occurring in sensitive lines are displayed in green, and regions of overlapping frequencies are shown in black.](JBB2011-474632.003){#fig3}

![Heatmap visualization of the miRNA expression of the 254 miRNAs (represented by 292 unique probes) that passed expression filtering criteria for the 21 most sensitive (yellow bar, low IC~50~) and 21 most resistant (blue bar, high IC~50~) to drug HKI-272. In total, 30 miRNAs were found to be significantly differentially expressed between the most sensitive and resistant lung cancer cell lines (LCCLs, orange bar). For this visualization, since a value of 4 represented no expression, all expression values were subtracted by 4 such that baseline expression would be shown as 0 (black).](JBB2011-474632.004){#fig4}

![Example of a miRNA showing differentially copy number alteration, differential miRNA expression, and differential target gene expression. (a) Copy number alteration comparison between cell lines which are highly resistant and sensitive to agent MG-132 revealed that the hsa-miR-10b locus, on chromosomal region 2q31.1, is more frequently gained in the highly resistant cell lines (*P* \< .05, Fisher\'s exact test). (b) miRNA expression analysis of miR-10b shows that expression is significantly higher in highly resistant cell lines as compared to sensitive cell lines to MG-132 (*P* = .03, Mann Whitney *U* test). (c) mRNA expression analysis of *RAD1*, a gene identified by bioinformatics prediction analysis as a putative target of miR-10b, shows anticorrelative expression to miR-10b expression. Specifically, decreased expression of RAD1 in highly resistant cell lines to MG-132 relative to highly sensitive lines is observed.](JBB2011-474632.005){#fig5}

![Overrepresented cellular and molecular functions that are common to all four sets of differentially expressed target genes. A "Core Analysis Comparison" was performed using Ingenuity Pathway Analysis and within the *Biological Functions*, only functions within *Molecular*and *Cellular Functions* were assessed. In total, eight of these functions were significant in all four sets. The orange threshold line corresponds to a *P*-value of  .05.](JBB2011-474632.006){#fig6}

###### 

List of miRNA with most frequent differential copy number alterations.

  miRNA            Significant drugs
  ---------------- -------------------------------
  hsa-mir-662      6 (AZ, Erl, Gel, Gö, HKI, MK)
  hsa-mir-124-2    5 (Erl, HKI, Ra, Sor, Sun)
  hsa-mir-1285-2   5 (MG, PF, PH, Ra, Sun)
  hsa-mir-548h-2   5 (Gel, HKI, MK, PD, Sor)
  hsa-mir-1208     4 (Cy, Erl, HKI, Sun)
  hsa-mir-1225     4 (AZ, Gö, MK, Sor)
  hsa-mir-1228     4 (Gel, MK, PF, TAE)
  hsa-mir-1299     4 (AZD, Erl, MK, PH)
  hsa-mir-147      4 (Erl, HKI, MK, TAE)
  hsa-mir-181a-2   4 (Erl, HKI, MK, TAE)
  hsa-mir-181b-2   4 (Erl, HKI, MK, TAE)
  hsa-mir-1827     4 (AZ, Gel, Pac, PF)
  hsa-mir-1972     4 (AZ, Gö, MK, Sor)
  hsa-mir-492      4 (Gel, Im, Pac, PF)
  hsa-mir-548c     4 (Gel, MK, PF, TAE)
  hsa-mir-548d-1   4 (Cy, Gö, HKI, Sun)
  hsa-mir-548f-2   4 (Gö, MG, PF, TAE)
  hsa-mir-600      4 (Erl, HKI, MK, TAE)
  hsa-mir-601      4 (Erl, HKI, MK, TAE)
  hsa-mir-940      4 (AZ, Gö, MK, Sor)

###### 

Most frequently different miRNAs at the expression level.

  miRNA          Significant drugs
  -------------- -----------------------------------
  hsa-mir-625    7 (Erl, Gö, HKI, MG, Pa, PHA, Ra)
  hsa-mir-130a   6 (Erl, Gö, HKI, MG, Pa, Sun)
  hsa-mir-148a   6 (AZ, Erl, Gel, Gö, HKI, Pa)
  hsa-mir-215    5 (Gel, Gö, MG, MK, Pa)
  hsa-mir-518b   5 (Cy, PF, PHA, Ra, Sun)
  hsa-mir-100    5 (Erl, Gö, HKI, Sun, TAE)
  hsa-mir-192    5 (Gel, Gö, MG, MK, Pa)
  hsa-mir-375    5 (Erl, Gel, Gö, HKI, Pa)
  hsa-mir-503    5 (Cy, Erl, MK, PHA, Ra)
  hsa-mir-193b   4 (AZ, MK, PHA, Ra)
  hsa-mir-521    4 (Cy, Erl, Im, PHA)
  hsa-mir-95     4 (Cy, Erl, MG, Sun)
  hsa-mir-194    4 (Gel, Gö, MG, Pa)
  hsa-mir-205    4 (Erl, Gel, Gö, HKI)
  hsa-mir-222    4 (AZ, Erl, Gel, HKI)
  hsa-mir-27a    4 (AZD, Erl, Gel, Gö)
  hsa-mir-377    4 (MG, Pa, Sor, Sun)
  hsa-mir-382    4 (AZD, MG, Pa, Sun)

###### 

List of miRNAs with significant copy number and expression alterations in the same drug.

  miRNA           Copy number alteration   Expression alteration        Drug in which significant
  --------------- ------------------------ ---------------------------- ---------------------------
  hsa-mir-10b     Gained, High IC~50~      Overexpressed, High IC~50~   MG-132
  hsa -mir-193b   Gained, High IC~50~      Overexpressed, High IC~50~   AZ628, MK-0457
  hsa-mir-328     Gained, High IC~50~      Overexpressed, High IC~50~   Geldanamycin
  hsa-mire-628    Gained, High IC~50~      Overexpressed, High IC~50~   PF-2341066

###### 

Differentially expressed mRNA targets for the four identified miRNAs.

  miRNA       10b                                 328                              193b                    193b                                628
  ----------- ----------------------------------- -------------------------------- ----------------------- ----------------------------------- ---------------------------------
  Drug        MG-132 (26S Proteasome inhibitor)   Geldanamycin (HSP90 inhibitor)   AZ628 (RAF inhibitor)   MK-0457 (Aurora kinase inhibitor)   PF-2341066 (MET, ALK inhibitor)
                                                                                                                                               
  Targets     *SMARCC1*                           *SLC16A1*                        *PHF15*                 *EIF2S1*                            *DCTD*
  *MKRN2*     *ANGEL1*                            *RPP30*                          *ARIH2*                 *NUP188*                            
  *CMTM6*     *UBR5*                              *RRP1B*                          *TMEM231*               *ELAC1*                             
  *CSDE1*     *SEMA3C*                            *EIF4B*                          *GABBR1*                *DACT1*                             
  *MAP4*      *MEIS2*                             *WDR48*                          *IKZF1*                 *CYP7B1*                            
  *MYO10*     *TRIM32*                            *PTPN21*                         *FKTN*                  *RPA4*                              
  *NKTR*      *GM2A*                              *CLEC2D*                         *GPATCH8*               *GAR1*                              
  *RYBP*      *EIF2S1*                            *MRPS16*                         *EZH1*                  *UCKL1*                             
  *ZNF532*    *RAC2*                              *NUDT15*                         *OLFML2A*               *IL7*                               
  *SENP5*     *OLFML2A*                           *NECAP2*                         *PSME3*                 *ABCE1*                             
  *CBL*       *HIP1*                                                               *AGTPBP1*               *CASP3*                             
  *WHSC1*     *PRKD3*                                                              *NMT2*                  *WBP4*                              
  *FOXJ2*     *VDR*                                                                *ADARB1*                *KLF9*                              
  *APOLD1*    *YME1L1*                                                             *GREB1*                 *ACTN2*                             
  *PEA15*     *TP63*                                                               *SMC5*                  *GPM6A*                             
  *RAD1*      *TFAP2C*                                                             *CCDC28A*               *LSM12*                             
  *CDC6*      *CHP2*                                                               *RNMT*                  *PRKCA*                             
  *UBE2K*     *STK24*                                                              *C15orf29*              *ADAT1*                             
  *BNIP2*     *GPR126*                                                             *RRP1B*                 *PBRM1*                             
  *PARD6B*    *SERTAD2*                                                            *AGPAT4*                *SP2*                               
  *FGD6*      *DSC2*                                                               *UBA52*                 *TRAIP*                             
  *MMP14*     *PTGIS*                                                              *GOSR1*                 *MAGOHB*                            
  *OLFML2A*   *RAB22A*                                                             *PRKD3*                                                     
  *GNL3L*     *FBXW2*                                                              *SYF2*                                                      
  *CTDSPL*    *HS2ST1*                                                             *SSX2IP*                                                    
  *MME*       *RPP30*                                                              *ANKH*                                                      
  *PPFIBP1*   *SLC16A3*                                                            *ZBTB39*                                                    
  *M6PR*      *MAN1A2*                                                             *KBTBD11*                                                   
  *KPNA6*     *TGIF2*                                                              *SEC16A*                                                    
  *RMI1*      *CLEC2D*                                                             *PHC3*                                                      
  *RBM15B*                                                                         *ZNF510*                                                    
  *SS18L2*                                                                         *RTF1*                                                      
                                                                                   *CYLD*                                                      
                                                                                   *WDR48*                                                     
                                                                                   *BTRC*                                                      
                                                                                   *CCNT2*                                                     
                                                                                   RAB36                                                       
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